Today, Novartis Vaccines has a strong global presence, most notably in Europe, with its centers of excellence in Germany, Italy and the UK—where we are among the leading suppliers of several crucial vaccines.
In 2007, Novartis won regulatory approval from the European Medicines Agency (EMEA) for an influenza vaccine derived from cultured cells instead of chicken eggs. Novartis Vaccines is also expanding in the US, building a large influenza cell culture plant in Holly Springs, North Carolina, and having established its global headquarters and a virology research center in Cambridge, Massachusetts, to mine the high concentration of scientific and industry expertise in the area.
The century-old culture of innovation seeded by Sclavo and von Behring infuses everything we do at Novartis Vaccines, as does our mission to alleviate suffering through the prevention of disease.
Discover up-to-date Novartis Vaccines information.
The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects.